SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4)

symbol:
SMARCA4
locus group:
protein-coding gene
location:
19p13.2
gene_family:
alias symbol:
hSNF2b|BRG1|BAF190|SNF2|SWI2|SNF2-BETA|SNF2LB|FLJ39786
alias name:
SNF2-like 4|global transcription...
entrez id:
6597
ensembl gene id:
ENSG00000127616
ucsc gene id:
uc060tnr.1
refseq accession:
NM_003072
hgnc_id:
HGNC:11100
approved reserved:
1995-07-17
19p13.2

SMARCA4(SWI/SNF相关基质相关肌动蛋白依赖染色质调节因子亚家族A成员4)属于SWI/SNF染色质重塑复合物基因家族,该家族通过调控染色质结构(DNA和蛋白质的紧密缠绕形式)影响基因表达。SMARCA4编码的蛋白质是BRG1(Brahma相关基因1),作为ATP依赖的染色质重塑酶,它利用能量改变DNA与组蛋白的结合状态,从而激活或抑制靶基因转录。其主要作用位点是染色质的核心区域,参与胚胎发育、细胞分化、DNA修复和细胞周期调控等关键生物学过程。若SMARCA4发生功能丧失性突变(如错义突变或截短突变),会导致染色质重塑异常,与多种癌症相关,包括恶性横纹肌样瘤(约98%病例存在突变)、非小细胞肺癌和卵巢癌等。这些突变通常造成复合物组装缺陷,使抑癌基因沉默或原癌基因激活。SMARCA4过表达可能破坏正常的基因调控网络,促进细胞增殖;而低表达则可能导致分化障碍或基因组不稳定。在SWI/SNF家族中,所有成员均含有保守的ATP酶结构域,但SMARCA4与SMARCA2(BRM)是唯一具有催化活性的亚基,二者功能部分冗余——当SMARCA4缺失时,SMARCA2可有限补偿。值得注意的是,约20%的人类肿瘤存在SWI/SNF复合物组分突变,凸显该家族在肿瘤抑制中的核心地位。目前针对SMARCA4缺失型肿瘤的治疗策略(如EZH2抑制剂)正进行临床试验,利用合成致死(synthetic lethality,即两个基因同时失活才导致细胞死亡)原理攻击癌细胞。

中文English

由该基因编码的蛋白质是SWI / SNF家族的蛋白质的成员,并且是类似于果??蝇的梵蛋白质。这个家庭的成员具有解旋酶和ATP酶活性,被认为通过改变周围这些基因的染色质结构调节某些基因的转录。所编码的蛋白质是大ATP依赖的染色质重塑复合SNF / SW I,这是需要的基因的转录活化通常通过染色质压抑的一部分。另外,这种蛋白质可以结合的BRCA1,以及调节致瘤蛋白的CD44的表达。这个基因导致横纹肌样瘤倾向的辨证分型2.多个转录变异体编码不同亚型的突变也发现了这种基因。 [由RefSeq的,2012年5月提供]

SMARCA4基因的碱基序列:[NCBI]
Loading Gene Browser...
蛋白质序列
1MSTPDPPLGG TPRPGPSPGP GPSPGAMLGP SPGPSPGSAH
41SMMGPSPGPP SAGHPIPTQG PGGYPQDNMH QMHKPMESMH
81 EKGMSDDPR YNQMKGMGMR SGGHAGMGPP PSPMDQHSQG
121YPSPLGGSEH ASSPVPASGP SSGPQMSSGP GGAPLDGADP
161Q ALGQQNRG PTPFNQNQLH QLRAQIMAYK MLARGQPLPD
201HLQMAVQGKR PMPGMQQQMP TLPPPSVSAT GPGPGPGPGP
241GP GPGPAPP NYSRPHGMGG PNMPPPGPSG VPPGMPGQPP
281GGPPKPWPEG PMANAAAPTS TPQKLIPPQP TGRPSPAPPA
321VPP AASPVM PPQTQSPGQP AQPAPMVPLH QKQSRITPIQ
361KPRGLDPVEI LQEREYRLQA RIAHRIQELE NLPGSLAGDL
401RTKA TIELK ALRLLNFQRQ LRQEVVVCMR RDTALETALN
441AKAYKRSKRQ SLREARITEK LEKQQKIEQE RKRRQKHQEY
481LNSIL QHAK DFKEYHRSVT GKIQKLTKAV ATYHANTERE
521QKKENERIEK ERMRRLMAED EEGYRKLIDQ KKDKRLAYLL
561QQTDEY VAN LTELVRQHKA AQVAKEKKKK KKKKKAENAE
601GQTPAIGPDG EPLDETSQMS DLPVKVIHVE SGKILTGTDA
641PKAGQLE AW LEMNPGYEVA PRSDSEESGS EEEEEEEEEE
681QPQAAQPPTL PVEEKKKIPD PDSDDVSEVD ARHIIENAKQ
721DVDDEYGV S QALARGLQSY YAVAHAVTER VDKQSALMVN
761GVLKQYQIKG LEWLVSLYNN NLNGILADEM GLGKTIQTIA
801LITYLMEHK RINGPFLIIV PLSTLSNWAY EFDKWAPSVV
841KVSYKGSPAA RRAFVPQLRS GKFNVLLTTY EYIIKDKHIL
881AKIRWKYMIV DEGHRMKNH HCKLTQVLNT HYVAPRRLLL
921TGTPLQNKLP ELWALLNFLL PTIFKSCSTF EQWFNAPFAM
961TGEKVDLNEE E TILIIRRL HKVLRPFLLR RLKKEVEAQL
1001PEKVEYVIKC DMSALQRVLY RHMQAKGVLL TDGSEKDKKG
1041KGGTKTLMNT IM QLRKICN HPYMFQHIEE SFSEHLGFTG
1081GIVQGLDLYR ASGKFELLDR ILPKLRATNH KVLLFCQMTS
1121LMTIMEDYFA YRG FKYLRL DGTTKAEDRG MLLKTFNEPG
1161SEYFIFLLST RAGGLGLNLQ SADTVIIFDS DWNPHQDLQA
1201QDRAHRIGQQ NEVR VLRLC TVNSVEEKIL AAAKYKLNVD
1241QKVIQAGMFD QKSSSHERRA FLQAILEHEE QDESRHCSTG
1281SGSASFAHTA PPPAG VNPD LEEPPLKEED EVPDDETVNQ
1321MIARHEEEFD LFMRMDLDRR REEARNPKRK PRLMEEDELP
1361SWIIKDDAEV ERLTCE EEE EKMFGRGSRH RKEVDYSDSL
1401TEKQWLKAIE EGTLEEIEEE VRQKKSSRKR KRDSDAGSST
1441PTTSTRSRDK DDESKKQ KK RGRPPAEKLS PNPPNLTKKM
1481KKIVDAVIKY KDSSSGRQLS EVFIQLPSRK ELPEYYELIR
1521KPVDFKKIKE RIRNHKYR S LNDLEKDVML LCQNAQTFNL
1561EGSLIYEDSI VLQSVFTSVR QKIEKEDDSE GEESEEEEEG
1601EEEGSESESR SVKVKIKLG RKEKAQDRLK GGRRRPSRGS
1641RAKPVVSDDD SEEEQEEDRS GSGSEED
结构预测来自 AlphaFold DB(UniProt: P51532),颜色表示 pLDDT 置信度(深蓝高、黄橙低)。
SMARCA4基因的碱基突变:           仅显示部分snp
rs7275       rs7935       rs9105       rs12012       rs881227       rs1019193       rs1019194       rs1029840       rs1050237       rs1122608       rs1529727       rs1529728       rs1529729       rs1801514       rs1804579       rs1865070       rs1968447      

SMARCA4基因在不同组织中的表达:    [UniProt]

基因在不同组织中的表达图
正向引物序列
正向Tm值
反向引物序列
反向Tm值
评分
CAGGATGAGGAGGAAGACG
59
TGAACAGATCAAACTCCTCCT
59
CCTCTAAAGGAGGAAGACGAG
59
TGAACAGATCAAACTCCTCCT
59
CAGGATGAGGAGGAAGACG
59
TGAACAGATCAAACTCCTCCT
59
CAGGATGAGGAGGAAGACG
59
TGAACAGATCAAACTCCTCCT
59
ACAGGGTAAGAAGGCTTCG
59
CCACGTACTCGTCTGTCTG
60
TACAAGGACAGCAGTGGAC
59
GATGAGCTCGTAGTACTCGG
60
GTTCGACCAGAAGTCCTCC
60
CAGTGTCTGCTCTCATCCT
59
ATCCAGAAGCTGACCAAGG
59
TCATCTTCAGCCATGAGCC
60
GGCTCCCTGATCTATGAAGAC
60
TTCACTGTCATCCTCCTTCTC
59
GAATCCTCACCAGGACCTG
60
CAGTGAGTCGCTGTAGTCC
60
转录因子
影响基因
影响类型
参考文献链接(PubMed)
SMARCA4
ABCG2
Activation
SMARCA4
CAD
Unknown
SMARCA4
CCND1
Repression
SMARCA4
CD44
Repression
SMARCA4
CDH1
Activation
SMARCA4
CDKN1A
Activation
SMARCA4
CDKN2A
Activation
SMARCA4
FOS
Repression
SMARCA4
MECOM
Activation
STAT1
SMARCA4
Unknown

SMARCA4基因(以及对应的蛋白质)的细胞分布位置:

[UniProt]     [GenomeNet]

" d="M482.414,245.296c3.539,4.293,4.455,10.009,0.202,11 c-4.244,0.996-4.983-10.983-8.293-8.438c-5.271,4.08,9.834,12.271,5.144,17.287c-3.717,3.607-6.172-5.75-10.839-1.976 c-4.673,3.776,6.781,7.299,2.831,11.326c-4.354,4.045-6.979-1.449-9.837-5.517c-1.193-1.742-2.059-3.851-3.595-2.748 c-1.516,1.078-1.854,1.795-0.938,3.666c2.374,4.854,9.235,10.119,5.156,12.535c-5.636,3.346-5.044-8.871-9.426-7.574 c-4.388,1.291,2.557,10.66-1.245,11.141c-4.089,0.545-3.483-10.239-6.979-8.575c-2.522,1.206-0.929,3.071-0.938,4.899 c0.004,1.32-0.964,3.6-2.372,4.062c-3.593,1.171-8.544-1.065-10.251-3.59c-6.04-8.93,0.396-15.997,4.639-7.015 c3.023,4.642,5.182,0.834,2.839-2.219c-1.032-1.354-4.309-5.901-0.781-7.252c2.904-1.113,4.271,1.941,5.985,4.592 c2.61,4.016,5.485,0.117,3.031-3.414c-1.828-2.633-2.74-3.803,3.156-7.42c6.405-4.369,6.52,3.869,10.077,0.646 c2.309-1.832-4.783-5.149,0.06-8.995c2.896-2.293,5.18,6.207,7.961,3.516c3.523-2.737-7.717-7.369,0.117-11.736 C473.413,240.77,480.519,242.891,482.414,245.296z"/> Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
  • 质膜
  • 细胞质
  • 细胞外
  • 高尔基体
  • 囊泡
  • 细胞骨架
  • 内质网
  • 细胞核
  • 内体
  • 溶酶体
  • 线粒体

SMARCA4基因的本体(GO)信息:

GO库代码
对应的蛋白质
来源代码
GO:0005524
A0A0A0MT49 (UniProtKB)
IEA
GO:0006355
A0A0A0MT49 (UniProtKB)
IEA
GO:0016514
A0A0A0MT49 (UniProtKB)
IEA
GO:0016887
A0A0A0MT49 (UniProtKB)
IEA
GO:0042393
A0A0A0MT49 (UniProtKB)
IEA
GO:0043044
A0A0A0MT49 (UniProtKB)
IEA
GO:0005634
K7EP28 (UniProtKB)
IDA
GO:0005730
K7EP28 (UniProtKB)
IDA
GO:0016514
K7EP28 (UniProtKB)
IEA
GO:0016887
K7EP28 (UniProtKB)
IEA
GO:0042393
K7EP28 (UniProtKB)
IEA
GO:0043044
K7EP28 (UniProtKB)
IEA
GO:0000122
P51532 (UniProtKB)
TAS
GO:0000790
P51532 (UniProtKB)
IDA
GO:0000790
P51532 (UniProtKB)
IDA
GO:0000790
P51532 (UniProtKB)
IDA
GO:0001105
P51532 (UniProtKB)
IDA
GO:0001164
P51532 (UniProtKB)
IDA
GO:0002039
P51532 (UniProtKB)
IPI
GO:0003407
P51532 (UniProtKB)
IEP
GO:0003713
P51532 (UniProtKB)
IMP
GO:0003713
P51532 (UniProtKB)
NAS
GO:0003714
P51532 (UniProtKB)
IDA
GO:0003714
P51532 (UniProtKB)
IDA
GO:0004386
P51532 (UniProtKB)
IEA
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005515
P51532 (UniProtKB)
IPI
GO:0005524
P51532 (UniProtKB)
IEA
GO:0005615
P51532 (UniProtKB)
IDA
GO:0005634
P51532 (UniProtKB)
IDA
GO:0005634
P51532 (UniProtKB)
IDA
GO:0005634
P51532 (UniProtKB)
IDA
GO:0005634
P51532 (UniProtKB)
IDA
GO:0005634
P51532 (UniProtKB)
IDA
GO:0005654
P51532 (UniProtKB)
TAS
GO:0005654
P51532 (UniProtKB)
TAS
GO:0005730
P51532 (UniProtKB)
IDA
GO:0005730
P51532 (UniProtKB)
IDA
GO:0006337
P51532 (UniProtKB)
IDA
GO:0006338
P51532 (UniProtKB)
IDA
GO:0006338
P51532 (UniProtKB)
IDA
GO:0006338
P51532 (UniProtKB)
IC
GO:0006338
P51532 (UniProtKB)
IMP
GO:0006351
P51532 (UniProtKB)
IEA
GO:0006357
P51532 (UniProtKB)
NAS
GO:0007070
P51532 (UniProtKB)
TAS
GO:0007286
P51532 (UniProtKB)
IEA
GO:0007399
P51532 (UniProtKB)
IEA
GO:0008094
P51532 (UniProtKB)
IGI
GO:0008134
P51532 (UniProtKB)
IPI
GO:0016020
P51532 (UniProtKB)
IDA
GO:0016514
P51532 (UniProtKB)
IDA
GO:0016514
P51532 (UniProtKB)
IDA
GO:0016514
P51532 (UniProtKB)
IDA
GO:0030177
P51532 (UniProtKB)
IMP
GO:0030308
P51532 (UniProtKB)
IMP
GO:0030957
P51532 (UniProtKB)
IPI
GO:0043044
P51532 (UniProtKB)
IDA
GO:0043234
P51532 (UniProtKB)
IDA
GO:0043923
P51532 (UniProtKB)
IMP
GO:0045892
P51532 (UniProtKB)
IDA
GO:0045892
P51532 (UniProtKB)
IMP
GO:0045893
P51532 (UniProtKB)
IMP
GO:0045944
P51532 (UniProtKB)
IDA
GO:0045944
P51532 (UniProtKB)
IDA
GO:0045944
P51532 (UniProtKB)
IGI
GO:0047485
P51532 (UniProtKB)
IPI
GO:0050681
P51532 (UniProtKB)
IPI
GO:0051091
P51532 (UniProtKB)
IDA
GO:0051091
P51532 (UniProtKB)
IDA
GO:0060766
P51532 (UniProtKB)
IMP
GO:0070182
P51532 (UniProtKB)
IPI
GO:0070577
P51532 (UniProtKB)
IDA
GO:0071564
P51532 (UniProtKB)
ISS
GO:0071564
P51532 (UniProtKB)
IDA
GO:0071565
P51532 (UniProtKB)
ISS
GO:1901838
P51532 (UniProtKB)
IMP
GO:1902661
P51532 (UniProtKB)
IDA
GO:1902895
P51532 (UniProtKB)
IMP
GO:1904837
P51532 (UniProtKB)
TAS
GO:2000134
P51532 (UniProtKB)
TAS
GO:0000978
P51532 (UniProtKB)
IDA
GO:0000980
P51532 (UniProtKB)
IDA
GO:0031492
P51532 (UniProtKB)
IDA
GO:0005524
Q9HBD4 (UniProtKB)
IEA
GO:0005634
Q9HBD4 (UniProtKB)
IDA
GO:0005730
Q9HBD4 (UniProtKB)
IDA
GO:0006355
Q9HBD4 (UniProtKB)
IEA
GO:0016514
Q9HBD4 (UniProtKB)
IEA
GO:0016887
Q9HBD4 (UniProtKB)
IEA
GO:0042393
Q9HBD4 (UniProtKB)
IEA
GO:0043044
Q9HBD4 (UniProtKB)
IEA

可能调控 SMARCA4基因的相关microRNA:     

BioGrid
IntAct
mentha
MINT
加载中…
关联基因 作用方式 资源库来源/分值
疾病名称 关系值 NofPmids NofSnps 来源
疾病名称 关系值 NofPmids NofSnps 来源
Coffin-Siris syndrome 0.240542884 3 0 BeFree_CTD_human_ORPHANET
MENTAL RETARDATION, AUTOSOMAL DOMINANT 16 0.24 1 6 CLINVAR_UNIPROT
Rhabdoid Tumor Predisposition Syndrome 2 0.24 0 9 CLINVAR_CTD_human
Coronary Artery Disease 0.12554839 5 3 BeFree_GAD_GWASCAT
Myocardial Infarction 0.124734064 1 2 GAD_GWASCAT
Coronary heart disease 0.122638474 3 4 BeFree_GAD_GWASCAT
Small cell carcinoma of lung 0.121357209 5 0 BeFree_CTD_human
Carcinoma, Small Cell 0.121085767 5 0 BeFree_CTD_human
Burkitt Lymphoma 0.120542884 3 0 BeFree_CTD_human
ovarian neoplasm 0.120271442 4 0 BeFree_CTD_human
Paediatric Therapeutic Development Workshop on rhabdoid tumours.
Montiel Equihua C, Molenaar JJ, Areso I, Biegel JA, Blanc P, Chi SN, Daems S, Danielson L, Drost J, Franke NE, Frühwald MC, Gajjar A, Geller JI, Huang A, Johann PD, Kearns P, Nysom K, O'Connor S, Ortiz MV, Parker J, Patel S, Patel S, Roberts CW, Williamson D, Yi JS, Pearson AD, Jenkinson D, Kool M, Bourdeaut F, LifeArc, Innovative Therapies for Children with Cancer ITCC, Cancer Research UK, Cancer Grand Challenge PROTECT team Br J Cancer IF: 7.8 2026-06-00
Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report.
Fu Z, Huang G, Xie J, Luo L, Ren Q, He H, Wang Y, Zhang J Front Oncol IF: 3.4 None
TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Hambelton GM, Pecci F, Makarem M, Gandhi MM, Garbo E, De Giglio A, Gagliano A, Sperandi F, Gelsomino F, Scalera S, Cipriani L, Marinelli D, Lamberti G, Shaverdian N, Haradon J, Nguyen T, Voligny E, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Rodig SJ, Pfaff K, Wang X, Rekhtman N, Sholl LM, Luo J, Johnson BE, Janne PA, Arvind R, Gainor JF, Maugeri-Saccà M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM J Thorac Oncol IF: 23.3 2026-07-00
Simultaneous CRISPR-on activation of TFAP2C and SMARCA4 promotes development of trophoblast-fate cells in bovine embryos†.
Alberio V, Savy V, Felipe MY, Fernandez-Martín R, Salamone DF Biol Reprod IF: 3.2 2026-05-13
Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.
Wei J, Zhang R, Li J, Li S, Yan X, Chen H, Guo H, Hu B, Liu Z, Guo J, Sheng X Oncologist IF: 4.7 2026-03-09
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.
Fiskus W, Mill CP, Issa GC, Piel J, Collins M, Hentemann M, Cuglievan B, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Senapati J, Loghavi S, Flores LB, Su X, DiNardo CD, Bhalla KN Blood IF: 23.9 2026-06-04
Design, synthesis and pharmacological evaluation of new SMARCA2 degraders bearing a furo[3,2-c]pyridazine scaffold.
Diao J, Jing H, Lin X, Wang Y, Lu Y, Xu L, Xiong C, Zhang A, Meng L, Zhang X, Song Z Eur J Med Chem IF: 6.7 2026-04-15
Clinicopathological and Genomic Analysis of SMARCA4-Deficient Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
Chen D, Zhang H, Wang D, Ye W, Zhao H, Zhang C, Wu S, Shi Q Cancer Manag Res IF: 2.6 None
SMARCA4-Deficient Carcinomas of the Small Intestine: A Systematic Review.
Syed A, Boumber Y, Malla M Curr Oncol IF: 3.6 2026-02-10

评论加载中...

登录后即可发表评论 登录 注册

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com